MTMuamer Terzo

Muamer Terzo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Muamer Terzo has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • UTICAJ APLIKACIJE RADIOFARMACEUTIKA NA KVALITET NUKLEARNOMEDICINSKIH SNIMAKA

    by Nusret Salkica, Muamer Terzo, Safet Hadžimusić, Enis Tinjak

    Radiofarmaci imaju ključnu ulogu u nuklearnoj medicini jer omogućavaju prikaz funkcionalnih i metaboličkih procesa u organizmu. Kvalitet nuklearnomedicinskih snimaka direktno zavisi od pravilnog izbora radiofarmaceutika, njegove pripreme i aplikacije. Faktori kao što su aplicirana aktivnost, radiohemijska čistoća, metoda aplikacije, vrijeme između aplikacije i snimanja te fiziološke karakteristike pacijenta značajno utiču na raspodjelu radiofarmaka i kvalitet dobivenih nuklearnomedicinskih slika. Pravilna aplikacija radiofarmaceutika omogućava optimalnu biodistribuciju radiofarmaka, povećava odnos signal–šum i doprinosi boljoj rezoluciji i kontrastu snimaka. Nepravilna aplikacija može dovesti do pojave artefakata, smanjene dijagnostičke tačnosti, neadekvatne kvantifikacije i/ili pogrešne interpretacije nalaza. Poseban značaj imaju ekstravazacija radiofarmaka, neadekvatna priprema pacijenta i odstupanja od standardiziranih protokola, koji negativno utiču na kvalitet nuklearnomedicinskih snimaka. Savremene nuklearnomedicinske metode, poput SPECT i PET dijagnostike, naročito zahtijevaju preciznu i standardiziranu primjenu radiofarmaceutika kako bi se osigurali pouzdani dijagnostički rezultati uz minimalnu izloženost pacijenta jonizirajućem zračenju. Cilj ovog rada je ukazati na značaj pravilne aplikacije radiofarmaka kao i analizirati faktore koji utiču na kvalitet nuklearnomedicinskih snimaka. Razumijevanje ovih faktora doprinosi unapređenju dijagnostičke tačnosti, sigurnosti pacijenata i ukupnog kvaliteta nuklearnomedicinskih procedura.

  • Open Access

    Prognostic Significance of Inflammatory Biomarkers in First-Line Immunotherapy for Metastatic Melanoma: Multicentric Study

    by Branko Dujovic, Aleksandar Popovic, Amina Jalovcic Suljevic, Bojana Cikota-Aleksic, Mirjana Balic, Igor Salatic, Jovana Pavlica, Philipp Schnecko, Tanja Mesti, Muamer Terzo, et al.

    Background/Objectives: This study evaluates the prognostic value of baseline inflammatory biomarkers, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), and pan-immune-inflammation value (PIV) in advanced cutaneous melanoma treated with first-line immunotherapy. Methods: This multicenter retrospective study included 162 patients with unresectable stage III/IV cutaneous melanoma treated with first-line pembrolizumab, nivolumab, or nivolumab plus ipilimumab. Biomarkers were calculated from complete blood counts obtained within 30 days before treatment start. Cut-offs were defined by ROC analysis. Progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan–Meier and Cox regression. Response was assessed by RECIST v1.1. Results: Higher baseline NLR, PLR, MLR, SII, and PIV were more common in patients with adverse baseline features, including liver metastases, elevated LDH, and poorer ECOG performance status. Patients with biomarker values below the cut-offs had significantly longer PFS and OS. In biomarker-specific multivariable models adjusted for selected clinical covariates, PIV retained the most consistent association with PFS and OS, while MLR was associated with PFS, and PLR with OS. Conclusions: Baseline inflammatory biomarkers from routine blood counts provide useful prognostic information in advanced melanoma treated with first-line ICIs. PIV showed the most consistent association with survival outcomes and may support initial risk stratification alongside LDH, ECOG, and metastasis pattern. However, prospective validation in independent cohorts is needed before routine clinical implementation.


  • Open Access

    Prognostic Significance of Inflammatory Biomarkers in First-Line Immunotherapy for Metastatic Melanoma: Multicentric Study

    by Branko Dujovic, Aleksandar Popovic, Amina Jalovcic Suljevic, Bojana Cikota-Aleksic, Mirjana Balic, Igor Salatic, Jovana Pavlica, Philipp Schnecko, Tanja Mesti, Muamer Terzo, et al.

    Background/Objectives: This study evaluates the prognostic value of baseline inflam-matory biomarkers neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII) and pan-immune-inflammation value (PIV) in advanced cutaneous melanoma treated with first-line immunotherapy. Methods: This multicenter retrospective study included 162 patients with unresectable stage III/IV cutaneous melanoma treated with first-line pembrolizumab, nivolumab, or nivolumab plus ipilimumab. Biomarkers were calculated from complete blood counts obtained within 30 days before treatment start. Cut-offs were defined by ROC analysis. Progression free survival (PFS) and overall survival (OS) were analyzed using Kaplan–Meier and Cox regression. Response was assessed by RECIST v1.1. Results: Higher baseline NLR, PLR, MLR, SII and PIV were more common in patients with adverse baseline features, including liver metastases, elevated LDH and poorer ECOG performance status. Patients with biomarker values below the cut-offs had sig-nificantly longer PFS and OS. In multivariable models adjusted for clinical covariates, PIV remained independently associated with the duration of PFS and OS; MLR inde-pendently predicted PFS, while PLR independently predicted OS. Conclusions: Baseline inflammatory biomarkers from routine blood counts provide useful prognostic information in advanced melanoma treated with first-line ICIs. PIV showed the most consistent independent association with survival outcomes and may support initial risk stratification alongside LDH, ECOG and metastasis pattern. However, prospective validation in independent cohorts is needed before routine clinical implementation.